Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.

Harding S, Provot F, Beuscart JB, Cook M, Bradwell AR, Stringer S, White D, Cockwell P, Hutchison CA.

Nephrol Dial Transplant. 2011 Apr;26(4):1438. doi: 10.1093/ndt/gfr019. Epub 2011 Mar 15.

PMID:
21406545
[PubMed - indexed for MEDLINE]
Free Article
2.

Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.

Granger Vallée A, Chenine L, Leray-Moragues H, Patrier L, Cognot C, Cartron G, Cristol JP, Canaud B.

Nephrol Dial Transplant. 2011 Nov;26(11):3627-33. doi: 10.1093/ndt/gfr180. Epub 2011 Apr 20.

PMID:
21508098
[PubMed - indexed for MEDLINE]
Free Article
3.

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G.

BMC Nephrol. 2008 Sep 22;9:11. doi: 10.1186/1471-2369-9-11.

PMID:
18808676
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.

Shum HP, Chan KC, Chow CC, Kho BC, Yan WW.

Hong Kong Med J. 2010 Dec;16(6):489-92.

PMID:
21135429
[PubMed - indexed for MEDLINE]
Free Article
5.

Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients.

Cohen G, Rudnicki M, Schmaldienst S, Hörl WH.

Nephrol Dial Transplant. 2002 May;17(5):879-83.

PMID:
11981077
[PubMed - indexed for MEDLINE]
Free Article
6.

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.

Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23.

PMID:
22273664
[PubMed - indexed for MEDLINE]
7.

Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.

Borrego-Hinojosa J, Pérez-del Barrio MP, Biechy-Baldan Mdel M, Merino-García E, Sánchez-Perales MC, García-Cortés MJ, Ocaña-Pérez E, Gutiérrez-Rivas P, Liébana-Cañada A.

Nefrologia. 2013;33(4):515-23. doi: 10.3265/Nefrologia.pre2013.Feb.11932. English, Spanish.

PMID:
23897183
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR.

J Am Soc Nephrol. 2007 Mar;18(3):886-95. Epub 2007 Jan 17.

PMID:
17229909
[PubMed - indexed for MEDLINE]
Free Article
9.

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.

Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P.

Trials. 2008 Sep 28;9:55. doi: 10.1186/1745-6215-9-55.

PMID:
18822172
[PubMed]
Free PMC Article
10.

Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P.

Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54. doi: 10.2215/CJN.04590908. Epub 2009 Apr 1.

PMID:
19339414
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N.

J Am Soc Nephrol. 2011 Jun;22(6):1129-36. doi: 10.1681/ASN.2010080857. Epub 2011 Apr 21.

PMID:
21511832
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.

Davenport A, Merlini G.

Nephrol Dial Transplant. 2012 Oct;27(10):3713-8. doi: 10.1093/ndt/gfs449.

PMID:
23114897
[PubMed - indexed for MEDLINE]
13.

Management options for cast nephropathy in multiple myeloma.

Cockwell P, Hutchison CA.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5. doi: 10.1097/MNH.0b013e32833ef72c. Review.

PMID:
20827195
[PubMed - indexed for MEDLINE]
14.

Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.

Martín-Reyes G, Toledo-Rojas R, Torres-de Rueda Á, Sola-Moyano E, Blanca-Martos L, Fuentes-Sánchez L, Martínez-Esteban MD, Díez-de los Ríos MJ, Bailén-García A, González-Molina M, García-González I.

Nefrologia. 2012;32(1):35-43. doi: 10.3265/Nefrologia.pre2011.Nov.11094. English, Spanish.

PMID:
22294003
[PubMed - indexed for MEDLINE]
Free Article
15.

Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney.

Grima DT, Airia P, Attard C, Hutchison CA.

Curr Med Res Opin. 2011 Feb;27(2):383-91. doi: 10.1185/03007995.2010.543125. Epub 2010 Dec 23.

PMID:
21175375
[PubMed - indexed for MEDLINE]
16.

[Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].

Shimizu K, Itoh J, Sugiura I, Tsushita K, Kosugi H, Nagura E.

Rinsho Ketsueki. 2006 Apr;47(4):303-9. Japanese.

PMID:
16715965
[PubMed - indexed for MEDLINE]
17.

Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.

Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K, Nakai S, Kato M, Ohashi A, Arai J, Hiki Y, Ishii J, Emi N, Sugiyama S, Yuzawa Y.

Ther Apher Dial. 2010 Oct;14(5):451-6. doi: 10.1111/j.1744-9987.2010.00863.x.

PMID:
21175542
[PubMed - indexed for MEDLINE]
18.

The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.

Cockwell P, Cook M.

Adv Chronic Kidney Dis. 2012 Sep;19(5):324-32. doi: 10.1053/j.ackd.2012.06.003. Review.

PMID:
22920643
[PubMed - indexed for MEDLINE]
19.

Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care.

Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P.

Artif Organs. 2008 Dec;32(12):910-7. doi: 10.1111/j.1525-1594.2008.00653.x.

PMID:
19133018
[PubMed - indexed for MEDLINE]
20.

Reversible acute kidney injury (AKI) by active removal of serum light chains in an HIV positive patient with myeloma kidney.

Sowole L, Burns A, Kaur B, Davenport A.

Clin Nephrol. 2011 Nov;76(5):417-20.

PMID:
22000564
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk